Overview

Treatment of Schizophrenic Patients With Ziprasidone

Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
To determine whether ziprasidone provides good efficacy and tolerability in the treatment of schizophrenic Greek patients.
Details
Lead Sponsor:
Pfizer
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Treatments:
Ziprasidone